Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases

被引:2
|
作者
Stanel, Stefan Cristian [1 ,2 ]
Rivera-Ortega, Pilar [1 ]
机构
[1] Univ Manchester, Wythenshawe Hosp, NHS Fdn Trust,North West Lung Ctr, Interstitial Lung Dis ILD Unit, Manchester, England
[2] Univ Manchester, Fac Biol, Med & Hlth, Manchester, England
关键词
progressive fibrosing interstitial lung disease; progressive pulmonary fibrosis; interstitial lung disease; idiopathic pulmonary fibrosis; PF-ILD; PPF; CHRONIC HYPERSENSITIVITY PNEUMONITIS; IDIOPATHIC PULMONARY-FIBROSIS; TELOMERE LENGTH; MULTIDISCIPLINARY;
D O I
10.3389/fmed.2023.1114722
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Acute exacerbations of progressive-fibrosing interstitial lung diseases
    Kolb, Martin
    Bondue, Benjamin
    Pesci, Alberto
    Miyazaki, Yasunari
    Song, Jin Woo
    Bhatt, Nitin Y.
    Huggins, John T.
    Oldham, Justin M.
    Padilla, Maria L.
    Roman, Jesse
    Shapera, Shane
    EUROPEAN RESPIRATORY REVIEW, 2018, 27 (150):
  • [22] Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
    Brown, Kevin K.
    Inoue, Yoshikazu
    Flaherty, Kevin R.
    Martinez, Fernando J.
    Cottin, Vincent
    Bonella, Francesco
    Cerri, Stefania
    Danoff, Sonye K.
    Jouneau, Stephane
    Goeldner, Rainer-Georg
    Schmidt, Martin
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    Wells, Athol U.
    RESPIROLOGY, 2022, 27 (04) : 294 - 300
  • [23] Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases
    Sterclova, Martina
    Sikorova, Katerina
    Petrek, Martin
    Vasakova, Martina
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [24] Imaging in the diagnosis and management of fibrosing interstitial lung diseases
    Lederer, Christoph
    Storman, Monika
    Tarnoki, Adam Domonkos
    Tarnoki, David Laszlo
    Margaritopoulos, George A.
    Prosch, Helmut
    BREATHE, 2024, 20 (01)
  • [25] Real-life prevalence of progressive fibrosing interstitial lung diseases
    Gagliardi, Maureen
    Vande Berg, Damienne
    Heylen, Charles-Edouard
    Koenig, Sandra
    Hoton, Delphine
    Tamirou, Farah
    Pieters, Thierry
    Ghaye, Benoit
    Froidure, Antoine
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [26] Effect of Genetic Background on Manifestation of Progressive Fibrosing Interstitial Lung Diseases
    Sterclova, M.
    Sikorova, K.
    Kishore, A.
    Petrek, M.
    Vasakova, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [27] Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib
    Makino, Shigeki
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 13 - 19
  • [28] Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype
    Takei, Reoto
    Brown, Kevin K.
    Yamano, Yasuhiko
    Kataoka, Kensuke
    Yokoyama, Toshiki
    Matsuda, Toshiaki
    Kimura, Tomoki
    Suzuki, Atsushi
    Furukawa, Taiki
    Fukuoka, Junya
    Johkoh, Takeshi
    Goto, Yoshihito
    Kondoh, Yasuhiro
    RESPIROLOGY, 2022, 27 (05) : 333 - 340
  • [29] Real-life prevalence of progressive fibrosing interstitial lung diseases
    Maureen Gagliardi
    Damienne Vande Berg
    Charles-Edouard Heylen
    Sandra Koenig
    Delphine Hoton
    Farah Tamirou
    Thierry Pieters
    Benoit Ghaye
    Antoine Froidure
    Scientific Reports, 11
  • [30] Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
    Aryeh Fischer
    Jörg Distler
    Clinical Rheumatology, 2019, 38 : 2673 - 2681